Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Radiology
Erschienen in: European Radiology 10/2021

14.04.2021 | Urogenital

Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018

verfasst von: Lucia Manganaro, Yulia Lakhman, Nishat Bharwani, Benedetta Gui, Silvia Gigli, Valeria Vinci, Stefania Rizzo, Aki Kido, Teresa Margarida Cunha, Evis Sala, Andrea Rockall, Rosemarie Forstner, Stephanie Nougaret

Erschienen in: European Radiology | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The recommendations cover indications for MRI examination including acquisition planes, patient preparation, imaging protocol including multi-parametric approaches such as diffusion-weighted imaging (DWI-MR),  dynamic contrast-enhanced imaging (DCE-MR) and standardised reporting. The document also underscores the value of whole-body 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) and highlights potential future methods.

Methods

In 2019, the ESUR female pelvic imaging working group reviewed the revised 2018 FIGO staging system, the up-to-date clinical management guidelines, and the recent imaging literature. The RAND-UCLA Appropriateness Method (RAM) was followed to develop the current ESUR consensus guidelines following methodological steps: literature research, questionnaire developments, panel selection, survey, data extraction and analysis.

Results

The updated ESUR guidelines are recommendations based on ≥ 80% consensus among experts. If ≥ 80% agreement was not reached, the action was indicated as optional.

Conclusions

The present ESUR guidelines focus on the main role of MRI in the initial staging, response monitoring and evaluation of disease recurrence. Whole-body FDG-PET plays an important role in the detection of lymph nodes (LNs) and distant metastases.

Key Points

• T2WI and DWI-MR are now recommended for initial staging, monitoring of response and evaluation of recurrence.
• DCE-MR is optional; its primary role remains in the research setting.
• T2WI, DWI-MRI and whole-body FDG-PET/CT enable comprehensive assessment of treatment response and recurrence
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Balleyguier C, Sala E, Da Cunha T et al (2011) Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology. Eur Radiol 21(5):1102–1110PubMedCrossRef
2.
Qin Y, Peng Z, Lou J, Liu H, Deng F, Zheng Y (2009) Discrepancies between clinical staging and pathological findings of operable cervical carcinoma with stage IB-IIB: a retrospective analysis of 818 patients. Aust N Z J Obstet Gynaecol 49(5):542–544
3.
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R (2018) Cancer of the cervix uteri. Int J Gynecol Obstet 143(Suppl 2):22–36
4.
Young P, Daniel B, Sommer G, Kim B, Herfkens R (2012) Intravaginal gel for staging of female pelvic cancers--preliminary report of safety, distention, and gel-mucosal contrast during magnetic resonance examination. J Comput Assist Tomogr 36(2):253
5.
Van Hoe L, Vanbeckevoort D, Oyen R, Itzlinger U, Vergote I (1999) Cervical carcinoma: optimized local staging with intravaginal contrast-enhanced MR imaging--preliminary results. Radiology 213(2):608–611PubMedCrossRef
6.
7.
8.
9.
Hori M, Kim T, Onishi H et al (2011) Uterine tumors: comparison of 3D versus 2D T2-weighted turbo spin-echo MR imaging at 3.0 T—initial experience. Radiology 258(1):154–163PubMedCrossRef
10.
Hwang J, Hong SS, Kim HJ et al (2018) Reduced field-of-view diffusion-weighted MRI in patients with cervical cancer. Br J Radiol 91(1087):20170864
11.
Moribata Y, Kido A, Fujimoto K et al (2017) Feasibility of computed diffusion weighted imaging and optimization of b-value in cervical cancer. Magn Reson Med Sci 16(1):66–72PubMedCrossRef
12.
Blackledge M, Leach M, Collins D, Koh D (2011) Computed diffusion-weighted MR imaging may improve tumor detection. Radiology 261(2):573–558PubMedCrossRef
13.
Signorelli M, Guerra L, Montanelli L et al (2011) Preoperative staging of cervical cancer: is 18-FDG-PET/CT really effective in patients with early stage disease? Gynecol Oncol 123(2):236–240
14.
Berek JS, Matsuo K, Grubbs BH (2019) Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri. J Gynecol Oncol 30(2):40CrossRef
15.
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R (2019) Corrigendum to “Revised FIGO stagingfor carcinoma of the cervix uteri”. Int J Gynecol Obstet 145:129–135CrossRef
16.
Lee SI, Atri M (2019) 2018 FIGO staging system for uterine cervical cancer: enter cross-sectional imaging. Radiology 292(1):15–24PubMedCrossRef
17.
Hricak H, Gatsonis C, Chi DS et al (2005) Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. Am J Clin Oncol 23(36):9329–9337CrossRef
18.
Xiao M, Yan B, Li Y, Lu J, Qiang J (2020) Diagnostic performance of MR imaging in evaluating prognostic factors in patients with cervical cancer: a meta-analysis. Eur Radiol 30(3):1405–1418PubMedCrossRef
19.
Thomeer MG, Gerestein C, Spronk S, van Doorn HC, van der Ham E, Hunink MG (2013) Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma:systematic review and meta-analysis. Eur Radiol 23:2005–2018PubMedCrossRef
20.
Woo S, Suh CH, Kim SY, Cho JY, Kim SH (2018) Magnetic resonance imaging for detection of parametrial invasionin cervical cancer: an updated systematic reviewand meta-analysis of the literature between 2012 and 2016. Eur Radiol 28(2):530–541PubMedCrossRef
21.
Epstein E, Testa A, Gaurilcikas A et al (2013) Early-stage cervical cancer: tumor delineation by magnetic resonance imaging and ultrasound - a European multicenter trial. Gynecol Oncol 128(3):449–453PubMedCrossRef
22.
Choi HJ, Ju W, Myung SK, Kim Y (2010) Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci 101(6):1471–1479PubMedCrossRef
23.
Liu B, Gao S, Li S (2017) A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a meta-analysis based on 67 studies. Gynecol Obstet Invest 82(3):209–222PubMedCrossRef
24.
Koh WJ, Abu-Rustum NR, Bean S et al (2019) Cervical Cancer, Version 3. 2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 17(1):64–84PubMedCrossRef
25.
Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N (2017) Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv72–iv83PubMedCrossRef
26.
Bentivegna E, Gouy S, Maulard A, Chargari C, Leary A, Morice P (2016) Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol 17(6):e240–e253PubMedCrossRef
27.
Slama J, Cerny A, Dusek L et al (2016) Results of less radical fertility-sparing procedures with omitted parametrectomy for cervical cancer: 5 years of experience. Gynecol Oncol 142:401–404PubMedCrossRef
28.
Plante M, Renaud MC, Sebastianelli A, Gregoire J (2017) Simple vaginal trachelectomy: a valuable fertility-preserving option in early-stage cervical cancer. Int J Gynecol Cancer 27:1021–1027PubMedCrossRef
29.
Póka R, Molnár S, Daragó P et al (2017) Intention-to-treat analysis of radical trachelectomy for early-stage cervical cancer with special reference to oncologic failures: single-institutional experience in Hungary. Int J Gynecol Cancer 27:1438–1445PubMedCrossRef
30.
Tomao F, Maruccio M, Preti EP et al (2017) Conization in early stage cervical cancer: pattern of recurrence in a 10-year single-institution experience. Int J Gynecol Cancer 27:1001–1008PubMedCrossRef
31.
Zhang Q, Li W, Kanis MJ et al (2017) Oncologic and obstetrical outcomes with fertility-sparing treatment of cervical cancer: a systematic review and meta-analysis. Oncotarget. 8:46580–46592PubMedPubMedCentralCrossRef
32.
33.
Woo S, Moon MH, Cho JY, Kim SH, Kim SY (2019) Diagnostic performance of MRI for assessing parametrial invasion in cervical cancer: a head-to-head comparison between oblique and true axial T2-weighted images. Korean J Radiol 20(3):378–384PubMedPubMedCentralCrossRef
34.
35.
Downey K, Attygalle AD, Morgan VA et al (2016) Comparison of optimised endovaginal vs external array coil T2-weighted and diffusion-weighted imaging techniques for detecting suspected early stage (IA/IB1) uterine cervical cancer. Eur Radiol 26:941–950PubMedCrossRef
36.
Li X, Wang L, Li Y, Song P (2017) The value of diffusion-weighted imaging in combination with conventional magnetic resonance imaging for improving tumor detection for early cervical carcinoma treated with fertility-sparing surgery. Int J Gynecol Cancer 27(8):1761–1768PubMedCrossRef
37.
DeSouza NM, Rockall A, Freeman S (2016) Functional MR imaging in gynecologic cancer. Magn Reson Imaging Clin N Am 24(1):205–222PubMedCrossRef
38.
Noël P, Dubé M, Plante M, St-Laurent G (2014) Early cervical carcinoma and fertility-sparing treatment options: MR imaging as a tool in patient selection and a follow-up modality. Radiographics 34(4):1099–1119PubMedCrossRef
39.
Rockall AG, Qureshi M, Papadopoulou I et al (2016) Role of imaging in fertility-sparing treatment of gynecologic malignancies. Radiographics 36(7):2214–2233PubMedCrossRef
40.
McEvoy SH, Nougaret S, Abu-Rustum NR et al (2017) Fertility-sparing for young patients with gynecologic cancer: how MRI can guide patient selection prior to conservative management. Abdom Radiol (NY) 42(10):2488–2512CrossRef
41.
Huang J-W, Song J-C, Chen T, Yang M, Ma Z-L (2019) Making the invisible visible: improving detectability of MRI-invisible residual cervical cancer after conisation by DCE-MRI. Clin Radiol 74(2):166.e15–166.e21CrossRef
42.
Sala E, Rockall AG, Freeman SJ, Mitchell DG, Reinhold C (2013) The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. Radiology 266(3):717PubMedCrossRef
43.
Raithatha A, Papadopoulou I, Stewart V, Barwick TD, Rockall AG, Bharwani N (2016) Cervical cancer staging: a resident’s primer: women’s imaging. Radiographics 36(3):933–934PubMedCrossRef
44.
Zhang A, Song J, Ma Z, Chen T. (2020) Application of apparent diffusion coefficient values derived from diffusion-weighted imaging for assessing different sized metastatic lymph nodes in cervical cancers. Acta Radiol 61(6):848–855. https://​doi.​org/​10.​1177/​0284185119879686​
45.
Qi Y-F, He Y-L, Lin C-Y et al (2020) Diffusion-weighted imaging of cervical cancer: feasibility of ultra-high b-value at 3T. Eur J Radiol 124:108779PubMedCrossRef
46.
Ruan J, Zhang Y, Ren H (2018) Meta-analysis of PET/CT detect lymph nodes metastases of cervical cancer. Open Med (Wars) 13:436–442CrossRef
47.
Cibula D, Potter R, Planchamp F (2018) The European Society of Gynaecological Oncology/European Society for Radiotherapy andOncology/European Society of Pathology guidelines forthe management of patients with cervical cancer. Int J Gynecol Cancer 28(4):641–655PubMedCrossRef
48.
49.
Gandy N, Arshad AM, Park W-HE, Rockall AG, Barwick TD (2019) FDG-PET imaging in cervical cancer. Semin Nucl Med 49(6):461–470
50.
Vincens E, Balleyguier C, Rey A et al (2008) Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy : correlation of radiologic findings with surgicopathologic results. Cancer 113(8):2158–2165PubMedCrossRef
51.
Gui B, Miccò M, Valentini AL et al (2019) Prospective multimodal imaging assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery-the “PRICE” study 2: role of conventional and DW-MRI. Eur Radiol 29(4):2045–2057PubMedCrossRef
52.
Thomeer MG, Vandecaveye V, Braun et al (2019) Evaluation of T2-W MR imaging and diffusion-weighted imaging for the early post-treatment local response assessment of patients treated conservatively for cervical cancer: a multicentre study. Eur Radiol 29(1):309–318PubMedCrossRef
53.
Jalaguier-Coudray A, Villard-Mahjoub R, Delouche A (2017) Value of dynamic contrastenhanced and diffusionweighted MR imaging in the detection of pathologic complete response in cervical cancer after neoadjuvant therapy: a retrospective observational study. Radiology 284(2):432–442PubMedCrossRef
54.
Levy A, Caramella C, Chargari C et al (2011) Accuracy of diffusion-weighted echo-planar MR imaging and ADC mapping in the evaluation of residual cervical carcinoma after radiation therapy. Gynecol Oncol 123:110–115PubMedCrossRef
55.
Schreuder SM, Lensing R, Stoker J, Bipat S (2015) Monitoring treatment response in patients undergoing chemoradiotherapy for locally advanced uterine cervical cancer by additional diffusion-weighted imaging: a systematic review. J Magn Reson Imaging 42(3):572–594PubMedCrossRef
56.
57.
Grigsby PW, Siegel BA, Dehdashti F et al (2004) Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 22(11):2167–2171PubMedCrossRef
58.
Onal C, Reyhan M, Guler OC, Yapar AF (2014) Treatment outcomes of patients with cervical cancer with complete metabolic responses after definitive Chemoradiotherapy. Eur J Nucl Med Mol Imaging 41(7):1336–1342PubMedCrossRef
59.
Beriwal S, Kannan N, Sukumvanich P et al (2012) Complete metabolic response after definitive radiation therapy for cervical cancer: patterns and factors predicting for recurrence. Gynecol Oncol 127(2):303–306PubMedCrossRef
60.
Lucas R, Lopes Dias J, Cunha TM (2015) Added value of diffusion-weighted MRI in detection of cervical cancer recurrence: comparison with morphologic and dynamic contrast-enhanced MRI sequences. Diagn Interv Radiol. 21(5):368–375
61.
Friedlander M, Grogan M, U.S. Preventative Services Task Force (2002) Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist. 7(4):342–347PubMedCrossRef
62.
O’Shannassy SJ, Brown KGM, Steffens D et al (2020) Referral patterns and outcomes of a highly specialised pelvic exenteration multidisciplinary team meeting . A retrospective cohort study. Eur J Surg Oncol 46(6):1138–1143PubMedCrossRef
63.
Laporte GA, Zanini LAG, Zanvettor PH (2020) Guidelines of the Brazilian Society of Oncologic Surgery for pelvic exenteration in the treatment of cervical cancer. J Surg Oncol 121(5):718–729PubMed
64.
65.
Gui B, Valentini AL, Miccò M et al (2016) Cervical cancer response to neoadjuvant chemoradiotherapy: MRI assessment compared with surgery. Acta Radiol 57(9):1123–1131PubMedCrossRef
66.
Oldan JD, Shah SN, Rose TL (2017) Applications of PET/MR imaging in urogynecologic and genitourinary cancers. Magn Reson Imaging Clin N Am 25(2):335–350PubMedCrossRef
67.
Vargas HA, Burger IA, Donati OF et al (2013) Magnetic resonance imaging/positron emission tomography provides a roadmap for surgical planning and serves as a predictive biomarker in patients with recurrent gynecological cancers undergoing pelvic exenteration. Int J Gynecol Cancer 23:1512e1519. 20CrossRef
68.
Barwick TD, Taylor A, Rockall A (2013) Functional imaging to predict tumor response in locally advanced cervical cancer. Curr Oncol Rep 15(6):549–558PubMedCrossRef
69.
Sawicki LM, Kirchner J, Grueneisen J et al (2018) Comparison of (18)F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study. Eur J Nucl Med Mol Imaging 45(4):622–629PubMedCrossRef
70.
71.
72.
73.
Nagasaka T et al (2012) The mean apparent diffusion coefficient value (ADCmean) on primary cervical cancer is a predictive marker for disease recurrence. Gynecol Oncol 127:478–483PubMedCrossRef
74.
Nakamura K, Joja I, Kodama J, Hongo A, Hiramatsu Y (2012) Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer. Eur J Nucl Med Mol Imaging 39:283–290PubMedCrossRef
75.
Yildirim BA, Onal C, Erbay G et al (2019) Prognostic values of SUVmax and ADCmean of the primary tumor in cervical cancer patients treated with definitive chemoradiotherapy. J Obstet Gynaecol 39:224–230CrossRef
76.
Gong J, Wang N, Bian L et al (2019) Cervical cancer evaluated with integrated 18F-FDG PET/MR. Oncol Lett 18:1815–1823PubMedPubMedCentral
77.
78.
Rizzo S, Botta F, Raimondi S et al (2018) Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp 2(1):36
79.
80.
Li Z, Li H, Wang S et al (2019) MR-based radiomics nomogram of cervical cancer in prediction of the lymph-vascular space invasion preoperatively. J Magn Reson Imaging 49(5):1420–1426
81.
Kan Y, Dong D, Zhang Y et al (2019) Radiomic signature as a predictive factor for lymph node metastasis in early-stage cervical cancer. J Magn Reson Imaging 49(1):304–310
82.
83.
84.
Ciolina M, Vinci V, Villani L et al (2019) Texture analysis versus conventional MRI prognostic factors in predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced cancer of the uterine cervix. Radiol Med 124(10):955–964PubMedCrossRef
85.
86.
87.
Rizzo S, Summers P, Raimondi S et al (2011) Diffusion-weighted MR imaging in assessing cervical tumour response to nonsurgical therapy. Radiol Med 116(5):766–780PubMedCrossRef
88.
Zhang Y, Chen JY, Xie CM et al (2011) Diffusion-weighted magnetic resonance imaging for prediction of response of advanced cervical cancer to chemoradiation. J Comput Assist Tomogr 35(1):102–107PubMedCrossRef
89.
Fu C, Bian D, Liu F, Feng X, Du W, Wang X (2012) The value of diffusion-weighted magnetic resonance imaging in assessing the response of locally advanced cervical cancer to neoadjuvant chemotherapy. Int J Gynecol Cancer 22(6):1037–1043PubMedCrossRef
90.
Kim SC, Gillet VG, Feldman S et al (2013) Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. Pharmacoepidemiol Drug Saf 22(11):1239–1244PubMedCrossRef
91.
Kuang F, Yan Z, Wang J, Rao Z (2014) The value of diffusion-weighted MRI to evaluate the response to radiochemotherapy for cervical cancer. Magn Reson Imaging 32(4):342–349PubMedCrossRef
92.
Fu C, Feng X, Bian D et al (2014) Simultaneous changes of magnetic resonance diffusion-weighted imaging and pathological microstructure in locally advanced cervical cancer caused by neoadjuvant chemotherapy. J Magn Reson Imaging 42(2):427–435
93.
Ju FJ (2016) Evaluation of the efficacy of chemoradiotherapy in cervical cancer using diffusion-weighted imaging and apparent diffusion coefficient. Onco Targets Ther 13(9):7555–7561CrossRef
94.
Rizzo S, Buscarino V, Origgi D et al (2016) Evaluation of diffusion-weighted imaging (DWI) and MR spectroscopy (MRS) as early response biomarkers in cervical cancer patients. Radiol Med 121(11):838–846PubMedCrossRef
95.
Gui B, Miccò M, Valentini AL et al (2018) Prospective multimodal imaging assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery-the "PRICE" study 2: role of conventional and DW-MRI. Eur Radiol 29(4):2045–2057
96.
Valentini AL, Miccò M, Gui B et al (2018) The PRICE study: The role of conventional and diffusion-weighted magnetic resonance imaging in assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery. Eur Radiol 28(6):2425–2435PubMedCrossRef
97.
Ho JC, Allen PK, Bhosale PR et al (2017) Diffusion-weighted magnetic resonance imaging as a predictor of outcome in cervical cancer after chemoradiation. Int J Radiat Oncol Biol Phys 97(3):546–553PubMedCrossRef
98.
Gladwish A, Milosevic M, Fyles A et al (2016) Association of apparent diffusion coefficient with disease recurrence in patients with locally advanced cervical cancer treated with radical chemotherapy and radiation therapy. Radiology 279(1):158–166PubMedCrossRef
99.
Onal C, Erbay G, Guler OC (2016) Treatment response evaluation using the mean apparent diffusion coefficient in cervical cancer patients treated with definitive chemoradiotherapy. J Magn Reson Imaging 44(4):1010–1019PubMedCrossRef
100.
Zhou W, Yang X, Dai Y, Wu Q, He G, Yin G (2016) Survey of cervical cancer survivors regarding quality of life and sexual function. J Cancer Res Ther 12(2):938–944PubMedCrossRef
101.
Himoto Y, Kido A, Fujimoto K et al (2015) MR imaging-based evaluation of morphological changes in the uterus and ovaries of patients following neoadjuvant chemotherapy for cervical cancer. Magn Reson Med Sci 14(1):65–72PubMedCrossRef
102.
Heo SH, Shin SS, Kim JW et al (2013) Pre-treatment diffusion-weighted MR imaging for predicting tumor recurrence in uterine cervical cancer treated with concurrent chemoradiation: value of histogram analysis of apparent diffusion coefficients. Korean J Radiol 14(4):616–625PubMedPubMedCentralCrossRef
103.
Nakamura K, Kajitani S, Joja I et al (2013) The posttreatment mean apparent diffusion coefficient of primary tumor is superior to pretreatment ADC mean of primary tumor as a predictor of prognosis with cervical cancer. Cancer Med 2(4):519–525PubMedPubMedCentralCrossRef
104.
Miccò M, Vargas HA, Burger IA et al (2014) Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. Eur J Radiol 83(7):1169–1176PubMedCrossRef
Metadaten
Titel
Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018
verfasst von
Lucia Manganaro
Yulia Lakhman
Nishat Bharwani
Benedetta Gui
Silvia Gigli
Valeria Vinci
Stefania Rizzo
Aki Kido
Teresa Margarida Cunha
Evis Sala
Andrea Rockall
Rosemarie Forstner
Stephanie Nougaret
Publikationsdatum
14.04.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 10/2021
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-07632-9

Weitere Artikel der Ausgabe 10/2021

European Radiology 10/2021 Zur Ausgabe

Interventional

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis

Oncology

Added value of [18F]FDG PET/MRI over MDCT alone in the staging of recurrent gastric cancer

Contrast Media

Investigating new CT contrast agents: a phantom study exploring quantification and differentiation methods for high-Z elements using dual-energy CT

Chest

Radiation dose reduction with the wide-volume scan mode for interstitial lung diseases

Cardiac

Assessment of myocardial deformation with CMR: a comparison with ultrasound speckle tracking

Chest

Tract metastasis in patients with long-term pleural catheter—computed tomography diagnosis and longitudinal assessment

Neu im Fachgebiet Radiologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise